Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: An italian multicenter study

Haematologica

Volumn 98, Issue 2, 2013, Pages 239-246

  Pagano, Livio ^a   Valentini, Caterina Giovanna ^a   Pulsoni, Alessandro ^b   Fisogni, Simona ^c   Carluccio, Paola ^d   Mannelli, Francesco ^e   Lunghi, Monia ^f   Pica, Gianmatteo ^g   Onida, Francesco ^h   Cattaneo, Chiara ⁱ   Piccaluga, Pier Paolo ^j   Di Bona, Eros ^k   Todisco, Elisabetta ^l   Musto, Pellegrino ^m   Spadea, Antonio ⁿ   D'Arco, Alfonso ^o   Pileri, Stefano ^j   Leone, Giuseppe ^a   Amadori, Sergio ^p   Facchetti, Fabio ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ Department of Hematology Spedali Civili ^*  (Italy)

^j UNIVERSITY OF BOLOGNA   (Italy)

^k SAN BORTOLO HOSPITAL   (Italy)

^l HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^m REFERRAL CANCER CENTER OF BASILICATA   (Italy)

ⁿ REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^o Division of Hematology   (Italy)

^p TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADULT; AGED; BONE MARROW; CLINICAL TRIAL; DENDRITIC CELL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPHENOTYPING; ITALY; LEUKEMIA; LYMPH NODE; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; DENDRITIC CELLS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOPHENOTYPING; ITALY; LEUKEMIA; LYMPH NODES; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84874536909     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.072645     Document Type: Article

References (37)

1. Facchetti F, Jones D, Petrella T. Blastic plasmacytoid dendritic cell neoplasm. In: Swerdlow SH, Campo E, Hazzis NL, et al, eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC press; 2008:145-7.
2. Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97(10):3210-7.
3. Pilichowska ME, Fleming MD, Pinkus JL, Pinkus GS. CD4+/CD56+ hematodermic neoplasm (blastic natural killer cell lymphoma): neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon. Am J Clin Pathol. 2007; 128(3):445-53.
4. Bueno C, Almeida J, Lucio P, Marco J, Garcia R, de Pablos JM, et al. Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica. 2004;89(1): 58-69.
5. Ng AP, Lade S, Rutherford T, McCormack C, Prince HM, Westerman DA. Primary cutaneous CD4+/CD56+ hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases. Haematologica. 2006;91(1): 143-4.
6. Jacob MC, Chaperot L, Mossuz P, Feuillard J, Valensi F, Leroux D, et al. CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica. 2003;88(8):941-55.
7. Facchetti F, Ungari M, Marocolo D, Lonardi S, Vermi W. Blastic plasmacytoid dendritic cell neoplasm. Hematology Meeting Reports 2009; 3(3):1-3.
8. Garnache-Ottou F, Feuillard J, Saas P. Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity? Br J Haematol. 2007;136(4):539-48.
9. Feuillard J, Jacob MC, Valensi F, Maynadié M, Gressin R, Chaperot L, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002;99(5):1556-63.
10. Cota C, Vale E, Viana I, Requena L, Ferrara G, Anemona L, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol. 2010;34(1):75-87.
11. Jardin F, Callanan M, Penther D, Ruminy P, Troussard X, Kerckaert JP, et al. Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease. Leukemia. 2009;23(4):698-707.
12. Chen J, Zhou J, Qin D, Xu S, Yan X. Blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol. 2011;29(2):e27-9.
13. Petrella T, Bagot M, Willemze R, Beylot- Barry M, Vergier B, Delaunay M, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol. 2005;123(5):662-75.
14. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-9.
15. Rossi JG, Felice MS, Bernasconi AR, Ribas AE, Gallego MS, Somardzic AE, et al. Acute leukemia of dendritic cell lineage in childhood: incidence, biological characteristics and outcome. Leuk Lymphoma. 2006;47 (4):715-25.
16. Jegalian AG, Buxbaum NP, Facchetti F, Raffeld M, Pittaluga S, Wayne AS, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95(11): 1873-9.
17. Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, et al. GOELAMS and GEIL study. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol. 2009;145(5):624-36.
18. Jegalian AG, Facchetti F, Jaffe ES. Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol. 2009;16(6):392-404.
19. Ferran M, Gallardo F, Ferrer AM, Salar A, Pérez-Vila E, Juanpere N, et al. Acute myeloid dendritic cell leukaemia with specific cutaneous involvement: a diagnostic challenge. Br J Dermatol. 2008;158(5):1129-33.
20. Wang H, Cao J, Hong X. Blastic plasmacytoid dendritic cell neoplasm without cutaneous lesion at presentation: case report and literature review. Acta Haematol. 2012;127 (2):124-7.
21. Rauh MJ, Rahman F, Good D, Silverman J, Brennan MK, Dimov N, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: case series and literature review. Leuk Res. 2012;36(1):81-6.
22. Tsagarakis NJ, Kentrou NA, Papadimitriou KA, Pagoni M, Kokkini G, Papadaki H, et al. Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. Leuk Res. 2010;34(4):438-46.
23. Leroux D, Mugneret F, Callanan M, Radford-Weiss I, Dastugue N, Feuillard J, et al. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique. Blood. 2002;99(11):4154-9.
24. Lucioni M, Novara F, Fiandrino G, Riboni R, Fanoni D, Arra M, et al. Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. Blood. 2011;118(17):4591-4.
25. Facchetti F, Pileri SA, Agostinelli C, Martelli MP, Paulli M, Venditti A, et al. Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2009;94(2):285-8.
26. Grossmann V, Schnittger S, Kohlmann A, Eder C, Roller A, Dicker F, et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood. 2012;120(15):2963-72.
27. Jardin F, Ruminy P, Parmentier F, Troussard X, Vaida I, Stamatoullas A, et al. TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol. 2011;153(3):413-6.
28. Dijkman R, van Doorn R, Szuhai K, Willemze R, Vermeer MH, Tensen CP. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood. 2007;109(4):1720-7
29. Reimer P, Rüdiger T, Kraemer D, Kunzmann V, Weissinger F, Zettl A, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32(7):637-46.
30. Suzuki R, Nakamura S, Suzumiya J, Ichimura K, Ichikawa M, Ogata K, et al. Blastic natural killer cell lymphoma/ leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement. Cancer. 2005;104(5):1022-31.
31. Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol. 2010;162(1):74-9.
32. Hashikawa K, Niino D, Yasumoto S, Nakama T, Kiyasu J, Sato K, et al. Clinicopathological features and prognostic significance of CXCL12 in blastic plasmacytoid dendritic cell neoplasm. J Am Acad Dermatol. 2012;66(2):278-91.
33. Dietrich S, Andrulis M, Hegenbart U, Schmitt T, Bellos F, Martens UM, et al. Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant. 2011;17(8):1250-4.
34. Voelkl A, Flaig M, Roehnisch T, Alpay N, Schmidmaier R, Oduncu F. Blastic plasmacytoid dendritic cell neoplasm with acute myeloid leukemia successfully treated to a remission currently of 26 months duration. Leuk Res. 2011;35(6):e61-3.
35. Male HJ, Davis MB, McGuirk JP, Abhyankar S, Aljitawi OS, Zhang D, et al. Blastic plasmacytoid dendritic cell neoplasm should be treated with acute leukemia type induction chemotherapy and allogeneic stem cell transplantation in first remission. Int J Hematol. 2010;92(2):398-400.
36. Ham JC, Janssen JJ, Boers JE, Kluin PM, Verdonck LF. Allogeneic stem-cell transplantation for blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol. 2012;30 (8):e102-3.
37. Facchetti F. Plasmacytoid dendritic cell neoplasms. In: Knowles Neoplastic Hematopathology, 3rd Edition (Orazi A, Weiss LM, Foucar KA, Knowles DM, Eds.), Lippincott Williams & Wilkins, Philadelphia PA, 2013. In press.